MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 5, 2008; DOI: 10.1124/mol.107.042176


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.042176v1
73/5/1394    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grund, E. M.
Right arrow Articles by Palmer, S. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grund, E. M.
Right arrow Articles by Palmer, S. S


Received for publication September 28, 2007.
Revised February 1, 2008.
Accepted for publication February 1, 2008.

TNF-{alpha} REGULATES INFLAMMATORY AND MESENCHYMAL RESPONSES VIA MEK, p38, NF-{kappa}B IN HUMAN ENDOMETRIOTIC EPITHELIAL CELLS

Eric Michael Grund 1, David Kagan 1, Cam Anh Tran 1, Andreas Zeitvogel 2, Anna Starzinski-Powitz 2, Selvaraj Nataraja 1, Stephen S Palmer 1*

1 EMD-Serono 2 Johann Wolfgang Goethe-Universitat

* Address correspondence to: E-mail: stephen.palmer{at}emdserono.com

Abstract

Tumor Necrosis Factor-alpha (TNF-{alpha}) is central to the endometriotic disease process. TNF-{alpha} receptor signaling regulates epithelial cell secretion of inflammation and invasion mediators. Since epithelial cells are a disease-inducing component of the endometriotic lesion, we explored the response of 12Z immortalized human epithelial endometriotic cells to TNF-{alpha}. This report reveals the impact of disruption of established TNF-{alpha} induced signaling cascades on the expression of biomarkers of inflammation and EMT (Epithelial-Mesenchymal Transition) from endometriotic epithelial cells. Importantly, we show the molecular potential of sTNF-R1 (TBP) and a panel of small molecule kinase inhibitors to block endometriotic gene expression, directly. TNF-{alpha} receptor is demonstrated to signal through IKK2>I{kappa}B>NF{kappa}{beta}, Erk>MEK, p38, and PI3K>Akt1/2. TNF-{alpha} induces the expression of transcripts for inflammatory mediators IL-6, IL-8, RANTES, TNF-{alpha}, GMCSF, MCP-1 and also invasion mediators MMP-7, MMP-9, and ICAM-1. Indeed, TBP inhibits the TNF-{alpha} induced expression of all the above endometriotic genes in 12Z endometriotic epithelial cells. The secretion of IL-6, IL-8, GMCSF, and MCP-1 by TNF-{alpha} fnis blocked by TBP. Interestingly, MEK, p38, and IKK inhibitors block TNF-{alpha} induced IL-8, IL-6 and GM-CSF secretion and 12z invasion while the PI3K inhibitors does not. The only inhibitor to block MCP-1 expression is the p38 inhibitor. Lastly, TBP, MEK inhibitor, or p38 inhibitor also block cell surface expression of N-cadherin, a marker of mesenchymal cells. Taken together these results demonstrate, that interruption of TNF-{alpha} induced signaling pathways in human endometriotic epithelial cells results in decreased expression and secretion of biomarkers for inflammation, EMT, and disease progression.


Key words: Interleukins, Tumor necrosis factor, MAP Kinase, Jun Kinase, P38 MAP Kinase, NFkappaB, Signaling network analyses





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics